Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Illinois Wellness Insider.
Press releases published on June 24, 2025
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer
GlobeNewswire
·
June 24, 2025
VANCOUVER, British Columbia and BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for …
Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation
GlobeNewswire
·
June 24, 2025
--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; on average, enobosarm 3mg significantly reduced body …
Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement
GlobeNewswire
·
June 24, 2025
CAMBRIDGE, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that the Company completed the second closing under …
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
GlobeNewswire
·
June 24, 2025
Good Tolerability and Robust Tumor Uptake were Observed in TNBC Animal Models Auger Emitters Offer the Potential Benefit of Enhanced Cytotoxicity, Safety and Ease-of-Use FLORHAM PARK, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. ( …
OneMedNet Announces Additional $3.7 Million of Funding in Private Placement Transactions and Approximately $11 Million in Reductions in Liabilities
GlobeNewswire
·
June 24, 2025
MINNEAPOLIS, June 24, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading provider of regulatory-grade imaging Real-World Data (iRWD), today announced that it has entered into agreements with accredited …
Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics
GlobeNewswire
·
June 24, 2025
Vancouver, Canada, June 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …
InnovAge PACE Sponsors Documentary Spotlighting National Crisis in Family Caregiving
GlobeNewswire
·
June 24, 2025
DENVER, June 24, 2025 (GLOBE NEWSWIRE) -- InnovAge, the nation’s largest provider of the Program of All-inclusive Care for the Elderly (PACE) based on participants served, announced today its sponsorship of the new PBS documentary Caregiving, airing …
Trinity Biotech Secures Key Regulatory Approval for Offshored and Outsourced Manufacturing of Its Flagship Rapid HIV Test, Accelerating Strategic & Financial Performance Transformation
GlobeNewswire
·
June 24, 2025
Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, Free Up Working Capital, and Enhance Scalability Transition to Outsourced Production Reduces Fixed Costs and Supports Trinity’s Broader Profitability and Growth Objectives …
Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
GlobeNewswire
·
June 24, 2025
RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profile Ethics approval and Phase 1 clinical trial start in prostate cancer anticipated in 2H 2025 SYDNEY and BUNDOORA, Australia, June 24, 2025 (GLOBE NEWSWIRE) …
Starton Therapeutics and Bend Bioscience Enter into Development Agreement for Oral Controlled Release Dosage Form of STAR-LLD (lenalidomide)
GlobeNewswire
·
June 24, 2025
PARAMUS, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, today announced a collaboration …
Medera’s Novoheart Enters New Collaboration to Develop Human Mini-Heart Models Aimed at Transforming Treatment for Hypoplastic Left Heart Syndrome
GlobeNewswire
·
June 24, 2025
First-ever mini-Heart models will be created from hypoplastic left heart syndrome (HLHS) patient stem cells, enabling personalized insights into their causes and treatments Partnership aims to improve survival and quality of life for pediatric HLHS …
Solésence to Join Russell 3000® and Russell 2000® Indexes
GlobeNewswire
·
June 24, 2025
ROMEOVILLE, Ill., June 24, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it will be added as a member of the broad-market …
SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes
GlobeNewswire
·
June 24, 2025
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, …
Pioneering New Study Finds Most U.S. Babies Lack Key Gut Bacteria, Increasing Risk for Allergies and Other Chronic Health Issues
GlobeNewswire
·
June 24, 2025
Initial findings published today in Communications Biology - a Nature portfolio journal - show that 76% of infants in the U.S. are deficient in Bifidobacterium, a gut microbiome genus responsible for the utilization of human milk oligosaccharides (HMOs) …
Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference
GlobeNewswire
·
June 24, 2025
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the …
PharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a Billion Dollar Market
GlobeNewswire
·
June 24, 2025
TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce that the United States Patent …
MindRank Announces Positive Phase 2b Results for AI-Designed Oral GLP-1 Receptor Agonist MDR-001 in Adults with Obesity or Overweight
GlobeNewswire
·
June 24, 2025
MDR-001 achieved statistically significant weight reductions of 8.2% to 10.3% at 24 weeks compared to 2.5% with placebo (p<0.00001), with up to 48.1% of participants achieving ≥10% weight loss. No treatment-related serious adverse events were reported. …
BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer
GlobeNewswire
·
June 24, 2025
Independent DSMB identifies no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor Review marks third consecutive positive recommendation by DSMB Study is being conducted under FDA …
Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing
GlobeNewswire
·
June 24, 2025
Comprehensive restructuring eliminates the potential issuance of up to 1.5 billion shares of common stock Plus Therapeutics files a request to withdraw the related resale registration statement with the SEC HOUSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Plus …
Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa
GlobeNewswire
·
June 24, 2025
- RDEB is a lifelong debilitating, blistering skin disease associated with large and painful wounds that often remain open for years and cause significant clinical burden, including pain, itch, and risk of squamous cell carcinoma - - ZEVASKYN™ (prademagene …